How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

368 results for

Uric Acid Nephrolithiasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies

recurrent kidney stones, and whether stone composition and pre- and post-treatment biochemistries predict treatment efficacy. Authors' conclusions Increased fluid intake, reduced soft drink consumption, thiazide diuretics, citrate pharmacotherapy, and allopurinol reduce risk of recurrent calcium stones. Effects of other dietary interventions appear mixed. We identified no RCTs for uric acid or cystine stones. Data regarding whether baseline or followup biochemistries predict treatment efficacy (...) Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Monga M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA

2012 Health Technology Assessment (HTA) Database.

22. Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis. (Full text)

and nephrolithiasis or renal/kidney stones have been suggested to be a common manifestation of disease in forms of uric acid, calcium phosphate or calcium oxalate. We performed a meta-analysis on five clinical trials and reported that correlation between IBD and formation of stone in renal system is positive and significant (Fix-effect model; CI: 95%, P <0.001, and randomeffect model; CI: 95%, P = 0.03).Based on the reports of the clinical trials, calcium oxalate is more prevalent in Crohn's disease (CD) than (...) Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis. The extra-intestinal manifestations of inflammatory bowel disease (IBD) are common and involve other organs or systems for example; urinary system.For this review, we used a variety of sources by searching through Web of Science, PubMed, EMBASE, Scopus and directory of open access journals (DOAJ).Urinary complications may occur in up to 22% of patients

2017 Journal of nephropathology

23. Multiple Sclerosis and Nephrolithiasis: A Matched Case Comparative Study. (Full text)

nephrolithotomy (PCNL; 25% vs 12%, P = 0.005) or a cystolithopaxy (16% vs 3%, P < 0.001) compared to their matched controls. In all, 61 patients had a complete 24-h urinary stone panel. There were no significant differences in urinary pH, volume, creatinine, calcium, citrate, oxalate, sodium, and uric acid as well as rates of hypocitraturia, hyperoxaluria, hypercalciuria, and hyperuricosuria among patients with MS. Use of intermittent straight catheterisation [ISC; odds ratio (OR) 3.50, 95% confidence (...) Multiple Sclerosis and Nephrolithiasis: A Matched Case Comparative Study. To compare stone composition and serum/urine biochemistries in stone formers with multiple sclerosis (MS) against stone formers without MS and to examine the association between mobility, methods of bladder emptying, and stone formation.In this retrospective case-control study, we identified patients diagnosed with MS and kidney stone disease who were seen at our institution between 2001 and 2016. For the first part

2017 BJU international

24. Association Between Sonographically Diagnosed Nephrolithiasis and Subclinical Coronary Artery Calcification in Adults. (PubMed)

of screening examination, physical activity, alcohol intake, smoking status, education level, body mass index, family history of cardiovascular disease, total energy intake, glucose concentration, systolic blood pressure, triglyceride concentration, high-density lipoprotein cholesterol concentration, uric acid concentration, and estimated glomerular filtration rate, the CAC score ratio was attenuated, but remained significant (CAC score ratio, 1.31; 95% CI, 1.00-1.71).Computed tomographic diagnosis (...) Association Between Sonographically Diagnosed Nephrolithiasis and Subclinical Coronary Artery Calcification in Adults. Although recent studies suggest an association between nephrolithiasis and clinical cardiovascular events, this association has been underexplored.Cross-sectional study.62,091 asymptomatic adults without known coronary heart disease who underwent a screening health examination that included cardiac tomography.Nephrolithiasis.Coronary artery calcification (CAC).Nephrolithiasis

2017 American Journal of Kidney Diseases

25. Etiopathogenesis of Nephrolithiasis in Ulcerative Colitis Patients with the Ileal Pouch Anal Anastomosis. (Full text)

and no nephrolithiasis.Using cross-sectional study design, serum and 24-hour urine metabolic compositions were compared between IPAA patients with nephrolithiasis (the study group) and those without (the control group). Urinary supersaturation of calcium oxalate, calcium phosphate, and uric acid was calculated.A total of 40 patients were enrolled in the study. There were no significant differences in serum electrolytes, vitamin D, parathyroid hormone, and kidney function tests between the study (n = 20) and control groups (...) Etiopathogenesis of Nephrolithiasis in Ulcerative Colitis Patients with the Ileal Pouch Anal Anastomosis. Our previous study showed that nephrolithiasis is a common complication in ulcerative colitis patients after ileal pouch anal anastomosis (IPAA). However, the pathogenesis of nephrolithiasis in IPAA patients has not been studied. The aim of this study was to compare urine and serum metabolic compositions in IPAA patients with nephrolithiasis and controls with IPAA

2017 Inflammatory Bowel Diseases

26. Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. (PubMed)

Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. Although the association between gout and nephrolithiasis is well known, the relationship between asymptomatic hyperuricemia and the development of nephrolithiasis is largely unknown.Cohort study.239,331 Korean adults who underwent a health checkup examination during January 2002 to December 2014 and were followed up annually or biennially through December 2014.Baseline serum uric acid levels of participants.The (...) development of nephrolithiasis during follow-up.Nephrolithiasis is determined based on ultrasonographic findings. A parametric Cox model was used to estimate the adjusted HRs of nephrolithiasis according to serum uric acid level.During 1,184,653.8 person-years of follow-up, 18,777 participants developed nephrolithiasis (incidence rate, 1.6/100 person-years). Elevated uric acid level was significantly associated with increased risk for nephrolithiasis in a dose-response manner (P for trend < 0.001) in men

2017 American Journal of Kidney Diseases

27. Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis

one year prior to randomisation or gout arthritis requiring uric acid lowering therapy Cystinuria at screening Hypokalemia (blood potassium level < 3 mmol/L) at screening Hyponatremia (blood sodium level < 125 mmol/L) at screening Pregnant and lactating women [pregnancy test to be performed for women of child-bearing potential (defined as women who are not surgically sterilized/ hysterectomized, and/ or who are postmenopausal for less than 12 months)] Previous (within 3 months prior (...) Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2017 Clinical Trials

28. Mature Vinegar Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis

. Secondary Outcome Measures : 24-h urine compositions [ Time Frame: 3 years ] Change in 24-h urine compositions (calcium excretion, oxalate excretion, etc.) serum calcium [ Time Frame: 3 years ] Change in serum calcium serum creatinine [ Time Frame: 3 years ] Change in serum creatinine serum uric acid [ Time Frame: 3 years ] Change in serum uric acid Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk (...) calcium oxalate or mixed (calcium oxalate and phosphate, calcium oxalate and uric acid) stone formation over the last 5 years; the stone had been removed completely confirmed by CT scan; No current treatment for the prevention of recurrent stones except for the advice to increase water intake; Residence in the area of Guangzhou, China; Written informed consent Exclusion Criteria: Obstructive uropathy, chronic urosepsis, renal failure (serum creatinine > 177 umol/L), renal tubular acidosis, primary

2017 Clinical Trials

29. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review (Full text)

Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review The association between uric acid (UA) on one side and systemic hypertension (Htn), dyslipidemia, glucose intolerance, overweight, fatty liver, renal disease and cardiovascular disease (CVD) on the other side is well recognized. However, the causal relationship between UA and these different clinical problems is still debatable. The recent years have witnessed hundreds of experimental and clinical trials (...) that favored the opinion that UA is a probable player in the pathogenesis of these disease entities. These studies disclosed the strong association between hyperuricemia and metabolic syndrome (MS), obesity, Htn, type 2 diabetes mellitus (DM), non-alcoholic fatty liver disease, hypertriglyceridemia, acute kidney injury, chronic kidney disease (CKD), coronary heart disease (CHD), heart failure and increased mortality among cardiac and CKD patients. The association between UA and nephrolithiasis

2016 Journal of advanced research

30. Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation

Universitaire de Nice More Information Go to Layout table for additonal information Responsible Party: Centre Hospitalier Universitaire de Nice ClinicalTrials.gov Identifier: Other Study ID Numbers: 15-AOI-07 First Posted: September 28, 2015 Last Update Posted: March 12, 2018 Last Verified: March 2018 Keywords provided by Centre Hospitalier Universitaire de Nice: Renal Ammonium ;uric acid Additional relevant MeSH terms: Layout table for MeSH terms Overweight Nephrolithiasis Body Weight Signs and Symptoms (...) Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2015 Clinical Trials

31. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86928/2018 Committee for Medicinal Products for Human Use (...) Ertu/Met ertugliflozin/metformin Ertu/Met pool pooled safety data from placebo-controlled ertugliflozin add-on metformin phase III studies ESFA European Food Safety Authority ESI-MS electrospray positive ionization mass spectra FA Focus area FAS full analysis set Assessment report EMA/86928/2018 Page 5/159 FDA Food and Drug Administration FDC fixed-dose combination FeCl 3 Iron (III) chloride Fpen Market penetration factor FPG fasting plasma glucose GAD glutamic acid decarboxylase GC gas

2018 European Medicines Agency - EPARs

32. Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86938/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) of Diabetes ECG electrocardiogram ECHA European Chemicals Agency eGFR estimated glomerular filtration rate ER excluding rescue ERA Environmental risk assessment ESI-MS electrospray positive ionization mass spectra FA Focus area FAS full analysis set FeCl 3 Iron (III) chloride Fpen Market penetration factor FPG fasting plasma glucose GAD glutamic acid decarboxylase GC gas chromatography GMP good manufacturing practice HCTZ hydrochlorothiazide HDL-C high-density lipoprotein-cholesterol HDPE high density

2018 European Medicines Agency - EPARs

33. Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86941/2018 Committee for Medicinal Products (...) Concentration L-PGA L-pyroglutamic acid LS least-squares MACE major adverse cardiovascular event MAR missing at random MNAR missing-not-at-random assumption MCAR missing completely at random MedDRA Medical Dictionary for Regulatory Activities mFAS modified FAS NDA New Drug Application NIR near infrared NMR nuclear magnetic resonance NMT not more than NOEC No Observed Effect Concentration PA polyamide PAR proven acceptable ranges PAT process analytical technology PD pharmacodynamic(s) PDLC pre-defined limit

2018 European Medicines Agency - EPARs

34. Renal ammonium excretion after an acute acid load: Blunted response in uric acid stone formers but not in patients with type 2 diabetes. (Full text)

Renal ammonium excretion after an acute acid load: Blunted response in uric acid stone formers but not in patients with type 2 diabetes. Idiopathic uric acid nephrolithiasis is characterized by elevated urinary net acid excretion and insufficient buffering by ammonium, resulting in excessively acidic urine and titration of the relatively soluble urate anion to insoluble uric acid. Patients with type 2 diabetes have similar changes in urinary pH, net acid excretion, and ammonium in 24-h urine (...) collections at baseline, even after controlling for dietary factors, and are at increased risk for uric acid nephrolithiasis. However, not all patients with type 2 diabetes develop kidney stones, suggesting that uric acid stone formers may have additional urinary defects, perhaps not apparent at baseline. We performed a metabolic study of 14 patients with idiopathic uric acid nephrolithiasis, 13 patients with type 2 diabetes, and 8 healthy control subjects of similar body mass index. After equilibration

2013 American Journal of Physiology. Renal physiology

35. MKSAP: 28-year-old man is evaluated for recurrent nephrolithiasis

), blood pressure is 131/78 mm Hg, pulse rate is 84/min, and respiration rate is 12/min. BMI is 22. The abdominal examination shows healed surgical incisions and is otherwise unremarkable. The remainder of the examination is normal. Laboratory studies, including complete blood count, electrolytes, and kidney function, are normal. Urinalysis is normal; 24-hour urine chemical analysis shows normal levels of calcium, citrate, and uric acid, but elevated oxalate. Plain abdominal radiographs show multiple (...) MKSAP: 28-year-old man is evaluated for recurrent nephrolithiasis Treatment for enteric hyperoxaluria and calcium oxalate nephrolithiasis MKSAP: 28-year-old man is evaluated for recurrent nephrolithiasis | | May 13, 2017 1 Shares Test your medicine knowledge with the , in partnership with the . A 28-year-old man is evaluated for recurrent nephrolithiasis. Medical history is significant for Crohn disease complicated by multiple small bowel strictures requiring resection. He began developing

2017 KevinMD blog

36. Uric acid and the kidney. (PubMed)

acid levels. Gout is rare in children; yet its presence necessitates evaluation for enzymatic defects in purine metabolism. Well-known effects of uric acid on the kidney include nephrolithiasis and acute kidney injury (AKI) in the setting of tumor lysis. However, recent data suggest that uric acid may be an important factor in the pathogenesis of AKI in general, as well as of chronic kidney disease (CKD) and hypertension. Hence, uric acid may not only be a marker but also a potential therapeutic (...) Uric acid and the kidney. Uric acid, the end product of purine metabolism, is excreted predominantly by the proximal tubules. Abnormal serum levels of uric acid are due to alterations in production or excretion. Fractional excretion of uric acid is helpful in determining the underlying etiology of hypouricemia or hyperuricemia in children. Abnormalities in the molecular mechanisms that control renal uric acid tubular transport are implicated in various disorders associated with abnormal uric

2014 Pediatric Nephrology

37. Significant differences in struvite and cystine stone frequency seen among Chinese nephrolithiasis patients living in North America compared to those living in China (Full text)

rates of calcium-based and uric acid calculi as well as urinary pH were seen among both groups.Significant differences exist between Chinese nephrolithiasis patients living in China compared to those living in North America, highlighting the importance of environmental factors in addition to genetics in modulating risk for urinary stone disease. (...) Significant differences in struvite and cystine stone frequency seen among Chinese nephrolithiasis patients living in North America compared to those living in China Interracial disparities in nephrolithiasis prevalence have been reported, but the interplay between genetics and the environment for urinary stone disease risk factors is poorly understood. To examine how environment may alter genetic predisposition for stone formation, we established the International Chinese Consortium

2016 Translational andrology and urology

38. Nephrolithiasis in elderly population; effect of demographic characteristics (Full text)

to be the case group and other subjects without a history of kidney stones served as control group. Demographic and anthropometric data, smoking, diabetes and metabolic syndrome (MetS), calcium (Ca), vitamin D, parathyroid hormone (PTH), uric acid and urine pH were compared in both groups.In this study, 1390 elderly people with the mean age of 69.37 ± 7.42 years were evaluated which 202 (14.53%) cases had renal stones. The patients with nephrolithiasis were younger (P = 0.010) and had higher uric acid (...) Nephrolithiasis in elderly population; effect of demographic characteristics Kidney stone (nephrolithiasis) is one of the most common diseases. During the past several decades, its prevalence and incidence have increased markedly in elderly population.This study was conducted to evaluate the risk factors for nephrolithiasis in elderly population.This study was based on the Amirkola Health and Ageing Project (AHAP). Elderly people with kidney stones in every size, type and number were considered

2016 Journal of nephropathology

39. Might E-cadherin promoter polymorphisms of rs16260 and rs5030625 associate with the risk of nephrolithiasis? (Full text)

(PCR-RLFP). Haplotype frequencies were also analyzed. To determine the association of rSNPs of CDH1 gene with the clinicopathological features of nephrolithiasis, nearly all possible etiological factors were documented. These factors were family history, gender, age, body mass index, liquid consumption, eating habits, tea-coffee and meat (oxalate rich) consumption, adequate physical activity, and all serum and urine levels-the serum levels of Na, K, Cl, phosphate, Ca, Mg, uric acid, albumin, blood (...) urea nitrogen (BUN), creatinine and serum parathyroid hormone (PTH) as well as 24 h urine excretions of creatinine, Na, K, Cl, phosphate, Ca, Mg, citrate, oxalate, uric acid, albumin and BUN.Significant differences were found between rs16260 and the risk of nephrolithiasis. Patients having CA genotype of rs16260 CDH1 polymorphism were associated with an almost trifold increased risk for developing kidney stone than those with the AA genotype (95 % CI 1.08-7.28, OR 2.8, P = 0.033). We also found

2016 SpringerPlus

40. Uric Acid Nephropathy (Overview)

acid into the more soluble compound allantoin. Three forms of kidney disease have been attributed to excess uric acid: acute uric acid nephropathy, chronic urate nephropathy, and uric acid nephrolithiasis. These disorders share the common element of excess uric acid or urate deposition, although the clinical features vary. [ ] Next: Pathophysiology Properties of uric acid Uric acid, the product of the xanthine oxidase–catalyzed conversion of xanthine and hypoxanthine, is the final metabolite (...) ), a condition that is also known as Lesch-Nyhan syndrome. This is an X-linked disorder that results in mental retardation, involuntary movement, self-mutilation, gout, and early kidney failure. In these patients, chronic uric acid overproduction causes hyperuricemia and uricosuria. The incidence of chronic kidney disease is high in these individuals, who have intratubular uric acid deposits and interstitial urate deposits. Uric acid nephrolithiasis Uric acid stones, which represent 5-10% of all renal

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>